Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Onux Medical

This article was originally published in The Gray Sheet

Executive Summary

Completion of $5 mil. second round financing Aug. 18 brings total funds raised since the firm's founding in 1998 to $9.5 mil., with contributions from initial investors Domain Associates and Delphi Ventures. The funds will help support the planned October launch of the Hampton, New Hampshire firm's 510(k)-cleared Touche Salute and Touche Grasper minimally invasive, needleless suturing technologies through distributors. The Salute is designed for use in hernia repair while the Grasper is intended for use in general and cardiac surgery. An international launch is planned by the second quarter of 2001. A portion of the funds also will support clinical trials in early 2001 for femoral artery closure and anastomosis indications, the firm says. "Trials for our femoral artery closure products and coronary artery bypass couplers will occur much quicker given these added resources," the firm says. The formation of a separate cardiovascular division in June "will allow us to focus specific energies on further development of our intellectual property in the exciting CV area," President and CEO Gregory Sancoff explains in a release

You may also be interested in...



Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel